Intrinsic Value

Stock has not been able to generate better return on equity than bank FD

ROE vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry Point

Red Flags Found

The DGTR has recommended the levy of Anti-Dumping Duty on Chinese drug imports. We discuss with Dinesh Dua, the Executive Director of Nectar Lifesciences that how does this impact their company and also understand the way forward for them.

#CNBCTV18 #BusinessNews #ShareMarketToday #Nifty #Sensex #DineshDua #NectarLifesciences

CNBC-TV18 is India's No.1 Business medium and the undisputed leader in business news. The channel's benchmark coverage extends from corporate news, financial markets coverage, expert perspective on investing and management to industry verticals and beyond. CNBC-TV18 has been constantly innovating with new genres of programming that helps make business more relevant to different constituencies across India. India's most able business audience consumes CNBC-TV18 for their information & investing needs. This audience is highly diversified at one level comprising of key groups such as business leaders, professionals, retail investors, brokers and traders, intermediaries, self-employed professionals, High Net Worth individuals, students and even homemakers but shares a distinct commonality in terms of their spirit of enterprise.

For latest news and updates visit our Website: https://bit.ly/2YbpXBM
Subscribe to our Channel: https://www.youtube.com/user/CNBCTV18
Like us on Facebook: https://www.facebook.com/cnbctv18india/
Follow us on Twitter: https://twitter.com/CNBCTV18News

Nectar Lifesciences' Dinesh Dua Speaks On Impact Of ATD Levied On Key Products | Chartbusters

The proceeds from sales of these assets will be used for repayment of Bank Loans.

Nectar Lifesciences stock ends 4.5% down after board nods sale of various assets to repay bank loans

Exchanges have changed the circuit filters for 546 stocks with 524 stocks seeing upward revision
while 22 stocks see downward revision.
Here are the key stocks that are in focus from the circuit filter changes

From 5% to 10%
IFCI Ltd
HCL Infosystems Ltd
Zuari Global Ltd
Goa Carbon Ltd
Panacea Biotec Ltd
Shree Renuka Sugars Ltd
Edelweiss Financial Services Ltd
Majesco Ltd
S Chand and Company Ltd
Hemisphere Properties India Ltd
 
From 10% to 20%
Bajaj Electricals Ltd
HFCL Ltd
Alkyl Amines Chemicals Ltd
HEG Ltd
Hindustan Copper Ltd
Igarashi Motors India Ltd
Venkys (India) Ltd
Linde India Ltd
JK Tyre & Industries Ltd
Nectar Lifesciences Ltd
Action Construction Equipment Ltd
 
From 5% to 20%
Hikal Ltd
Adani Power Ltd
Angel Broking Ltd
 
From 10% to 5%
PNB Housing Finance Ltd
5paisa Capital Ltd
Subscribe To ET Now For Latest Updates On Stocks, Business, Trading | ► https://goo.gl/SEjvK3

Subscribe Now To Our Network Channels :-
Times Now  : http://goo.gl/U9ibPb
The NewsHour Debate : http://goo.gl/LfNgFF

To Stay Updated Download the Times Now App :-
Android Google Play :  https://goo.gl/zJhWjC
Apple App Store :  https://goo.gl/d7QBQZ

Social Media Links :-
Twitter - http://goo.gl/hA0vDt
Facebook - http://goo.gl/5Lr4mC
G+ - http://goo.gl/hYxrmj
Website - www.etnownews.com

Circuit limits changed for 546 stocks

#CNBCAwaazLive #AajKaTajaKhabar #BusinessNewsLive #StockMarketLive #ShareMarketLive

Nectar Lifesciences काफी तेजी से आगे बढ़ रहा है। Stop Loss के साथ इस stock को Trade करने की राय दी गई है। वहीं, Pharma sector में  Ind-swift Labs में खरीदारी की राय दी गई है, देखें वीडियो

CNBC Awaaz is India’s number one business channel and an undisputed leader in business news and information for the last ten years. Our channel aims to educate, inform and inspire consumers to go beyond limitations, with practical tips on personal finance, investing, technology, consumer goods and capital markets. Policymakers and business owners alike have grown to trust CNBC Awaaz as the most reliable source with its eye on India’s business climate. Our programming gives consumers a platform to make decisions with confidence.

Subscribe to the CNBC Awaaz YouTube channel here: https://tinyurl.com/y5rsvesk

Follow CNBC Awaaz on Twitter: https://twitter.com/CNBC_Awaaz
Like us on our CNBC Awaaz Facebook page: https://www.facebook.com/cnbcawaaz
Website: https://bit.ly/3230WJW

NECTAR LIFESCIENCES है मजबूती वाला Stock?, जानें क्या है खरीदारी पर राय? | Seedha Sauda | CNBC Awaaz

Chandigarh-based Nectar Lifesciences Ltd (NLL) on Saturday said its Board of Directors have decided to opt for one-time restructuring of its debt.“The Board of Directors in their meeting held on Novem

Nectar Lifesciences board opt for one-time debt restructuring

Borosil Renewables, Hathway Bhawani Cabletel, Dalmia Bharat Sugar, Nectar Lifesciences, Bilcare and Satin Creditcare Network have rallied over 100% in the past one month

Kaya, Alok Industries, Birla Tyres and 35 others rally over 100% in 1 month

Panacea Biotec, Nectar Lifesciences, and Vimta Labs, too, were frozen at 20 per cent upper circuit on the BSE.

Mid, small-cap pharma stocks rally; Dishman Carbogen, Unichem Labs soar 20%

Asahi Songwon Colors, Galaxy Surfactants, Nectar Lifesciences are also among the stocks in the news today.

In pics | Stocks in the news: Sun Pharma, Hindalco, Dalmia Bharat Sugar, Metropolis Health

Dinesh Dua, CEO & Director, Nectar Lifesciences states that the company has had a robust performance in topline & bottomline.

Have Had A Robust Performance In Topline & Bottomline: Nectar Lifesciences

Dinesh Dua, Nectar Lifesciences on the nod for API manufacturing in Punjab

Halftime Report: Dinesh Dua, Nectar Lifesciences - May 18

Dinesh Dua CEO, Nectar Lifesciences joins us to clarify on the news of stake sale

Bazaar - Dinesh Dua CEO, Nectar Lifesciences - 09 June 2014

Nectar Lifesciences Limited is an India-based integrated pharmaceutical organization. The Company has developed fully integrated sustainable production systems to manufacture cephalosporin intermediates, active pharmaceuticals ingredients (APIs) and finished dosage formulations (FDF or Formulations) to meet the diverse requirements of its customer base in India and approximately 75 countries worldwide. The Company operates only in the business segment of Pharmaceuticals Products. The Company’s products include Cefixime, Cefuroxime Axetil, Ceftriaxone Sodium, and Menthol and its derivatives. The Company’s subsidiaries include Nectar Lifesciences USA, LLC; Nectar Lifesciences UK Limited, United Kingdom and Neclife PT, Unipessoal LDA, Portugal.

Nectar Lifesciences Ltd

Nectar Lifesciences Ltd

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

News Video

Nectar Lifesciences' Dinesh Dua Speaks On Impact Of ATD Levied On Key Products | Chartbusters

Nectar Lifesciences stock ends 4.5% down after board nods sale of various assets to repay bank loans

News Video

Circuit limits changed for 546 stocks

News Video

NECTAR LIFESCIENCES है मजबूती वाला Stock?, जानें क्या है खरीदारी पर राय? | Seedha Sauda | CNBC Awaaz

Nectar Lifesciences board opt for one-time debt restructuring

Kaya, Alok Industries, Birla Tyres and 35 others rally over 100% in 1 month

Mid, small-cap pharma stocks rally; Dishman Carbogen, Unichem Labs soar 20%

Nectar Lifesciences Ltd

Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

News Video

Nectar Lifesciences' Dinesh Dua Speaks On Impact Of ATD Levied On Key Products | Chartbusters

Nectar Lifesciences stock ends 4.5% down after board nods sale of various assets to repay bank loans

News Video

Circuit limits changed for 546 stocks

News Video

NECTAR LIFESCIENCES है मजबूती वाला Stock?, जानें क्या है खरीदारी पर राय? | Seedha Sauda | CNBC Awaaz

Nectar Lifesciences board opt for one-time debt restructuring

Kaya, Alok Industries, Birla Tyres and 35 others rally over 100% in 1 month

Mid, small-cap pharma stocks rally; Dishman Carbogen, Unichem Labs soar 20%

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock